DOCSLIB.ORG

Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020 STATE OF THE ART REVIEW Management of hypertriglyceridemia BMJ: first published as 10.1136/bmj.m3109 on 12 October 2020. Downloaded from Vinaya Simha ABSTRACT Hypertriglyceridemia is one of the most common lipid abnormalities encountered in clinical practice. Many monogenic disorders causing severe hypertriglyceridemia have been identified, but in most patients triglyceride elevations result from a Division of Endocrinology, Mayo combination of multiple genetic variations with small effects and environmental Clinic, Rochester, MN 55905, USA factors. Common secondary causes include obesity, uncontrolled diabetes, alcohol Correspondence to: misuse, and various commonly used drugs. Correcting these factors and optimizing [email protected] Cite this as: BMJ 2020;371:m3109 lifestyle choices, including dietary modification, is important before starting http://dx.doi.org/10.1136/bmj.m3109 drug treatment. The goal of drug treatment is to reduce the risk of pancreatitis in Series explanation: State of the Art Reviews are commissioned patients with severe hypertriglyceridemia and cardiovascular disease in those on the basis of their relevance with moderate hypertriglyceridemia. This review discusses the various genetic and to academics and specialists in the US and internationally. acquired causes of hypertriglyceridemia, as well as current management strategies. For this reason they are written predominantly by US authors. Evidence supporting the different drug and non-drug approaches to treating hypertriglyceridemia is examined, and an easy to adopt step-by-step management strategy is presented. Introduction independent risk factor for ASCVD and optimal drug Hypertriglyceridemia is a fairly common clinical treatment, including novel and emerging therapies, condition, but it continues to evoke considerable to mitigate this will be examined in greater detail. http://www.bmj.com/ debate about its ramifications and management. Consider the clinical vignette in box 1. Even as the Sources and selection criteria diagnosis of hypertriglyceridemic acute pancreatitis I searched PubMed for English language articles (HTG-AP) seems relatively straightforward, the published in peer reviewed journals over the clinician is confronted by quite a few conundrums. past two decades. Search terms used included Is hypertriglyceridemia a cause or a consequence hypertriglyceridemia management, hypertriglyceri- of acute pancreatitis? Are previous non-fasting demic pancreatitis, hypertriglyceridemia and cardio- serum triglyceride values valid for diagnosing vascular risk, drug-induced dyslipidemia, and on 21 October 2020 by guest. Protected copyright. hypertriglyceridemia and assessing future risk? What genetic hypertriglyceridemia. I included consensus is the cause of the patient’s hypertriglyceridemia: statements, guidelines, and systematic reviews primary genetic abnormality or secondary to un- from 2010 to 2020 and also considered randomized controlled diabetes and estrogen use? Would genetic controlled trials (RCTs) and human pathophysiology testing have any benefit? What is the optimal studies from earlier (from 1970). I prioritized RCTs, treatment plan for the elevated triglycerides, both systematic reviews with meta-analyses, and large acutely to relieve pancreatitis and in the long term case series, in that order, when evaluating treatment to prevent its recurrence? Does hypertriglyceridemia effects. Case reports were excluded, but some increase her long term risk of atherosclerotic observational studies detailing the epidemiology cardiovascular disease (ASCVD)? What is the optimal and pathophysiology of the disease were included. diet that should be recommended, especially in view of her preference for a “ketogenic” diet? Which drug Diagnosis and classification treatment will benefit her the most: statins, fibrates, The mean age adjusted serum triglyceride omega-3 fatty acids, niacin, or a combination? concentrations of US adult men and women were This review summarizes relevant data to help to reported to be 128 (5th-95th percentile 52-361) answer some of these questions. The target audience mg/dL and 110 mg/dL (48-270), respectively, in the is general internists, hospital based physicians, 1999-2008 National Health and Nutrition Examina- endocrinologists, and cardiologists. It outlines the tion Survey (NHANES).1 Serum triglycerides tend epidemiology and changing trends of dyslipidemia in to increase with age and are lower in children. the general population, the different classifications Hypertriglyceridemia is commonly defined as fasting of the severity of hypertriglyceridemia, and the serum triglycerides of 150 mg/dL (1.7 mmol/L) or pathophysiology of hypertriglyceridemia and its above, although the “optimal” fasting triglyceride complications. The role of hypertriglyceridemia as an concentration, which confers the lowest risk of incident the bmj | BMJ 2020;371:m3109 | doi: 10.1136/bmj.m3109 1 STATE OF THE ART REVIEW Furthermore, non-fasting serum triglycerides have Box 1: Clinical vignette BMJ: first published as 10.1136/bmj.m3109 on 12 October 2020. Downloaded from also been shown to be associated with risk of acute A 46 year old woman with recently diagnosed type 2 diabetes was admitted with pancreatitis, with a hazard ratio exceeding that for severe abdominal pain, nausea, and vomiting. Abdominal imaging and elevated ASCVD.8 Non-fasting triglycerides may better reflect serum lipase concentrations confirmed the diagnosis of acute pancreatitis. At the postprandial accumulation of atherogenic presentation, her plasma glucose was 306 mg/dL and her serum triglycerides were triglyceride-rich remnant lipoprotein particles 1850 mg/dL. Two months previously, her fasting plasma glucose was 155 mg/dL, her and thus better predict the risk for ASCVD than do hemoglobin A1c was 7.6%, and she had been treated with metformin monotherapy. fasting triglyceride concentrations. Accordingly, She had also been given hormone replacement therapy for menopausal symptoms the European and Canadian guidelines do not and moderate intensity statin therapy for primary prevention of atherosclerotic advocate a fasting lipid profile,5 9 and the recent cardiovascular disease. She had generalized obesity with a body mass index of 35. AHA/ACC guidelines recommend either a fasting or Review of previous medical records showed serum triglyceride concentrations ranging a non-fasting lipid profile for screening, although from 265 to 440 mg/dL, although some measurements were obtained in a non-fasting a follow-up fasting lipid profile is recommended if state. Her family history was significant for hypercholesterolemia and premature serum triglycerides are above 400 mg/dL.3 These coronary artery disease but not for pancreatitis or severe hypertriglyceridemia. recommendations are intended to simplify screening procedures, as an elevation of only 15-20% in serum triglycerides is seen after a regular low fat meal (about and recurrent ASCVD, may be below 100 mg/dL.1 15 g fat), which would be inconsequential in people Different guidelines and expert committees have with normal triglyceride concentrations. However, designated different cut-off values for classification in the absence of established normal standards for of the severity of hypertriglyceridemia (table 1). postprandial triglyceride concentrations, fasting The US National Cholesterol Education Program triglycerides are still recommended for the diagnosis (NCEP) Adult Treatment Panel,2 and the subsequent and classification of hypertriglyceridemia. The American Heart Association/American College of postprandial triglyceride responses to a standardized Cardiology (AHA/ACC) guidelines on lipid treatment,3 test meal that would best predict future ASCVD or considered serum triglycerides of 500 mg/dL or above pancreatitis remain to be determined. as severe hypertriglyceridemia indicative of risk for pancreatitis, with lesser elevations (borderline and Epidemiology borderline high) associated with increased ASCVD Hypertriglyceridemia is the most common form of risk. They note that patients with triglycerides dyslipidemia observed in the general population. in the 500-999 mg/dL (5.6-11.2 mmol/L) range On the basis of the NHANES 2003-06 data,10 an are at risk of developing unrecognized marked estimated 53% of US adults have dyslipidemia, http://www.bmj.com/ increases in triglycerides, leading to pancreatitis. As 27% have elevated low density lipoprotein (LDL) pancreatitis is rarely seen with serum triglycerides cholesterol, 23% have low high density lipoprotein below 1000 mg/dL, the Endocrine Society and (HDL) cholesterol, and 30% have elevated serum European Atherosclerosis Society/European Society triglycerides (>150 mg/dL). However, encouraging of Cardiology classify severe hypertriglyceridemia as trends have been noted, with a steady decline in the concentrations of at least 1000 mg/dL or 10 mmol/L prevalence of hypertriglyceridemia from 33.3% in the .4 5 11 (880 mg/dL), respectively 2001-04 survey to 25.1% in the 2009-12 survey. on 21 October 2020 by guest. Protected copyright. The above classifications are based on fasting According to the 2007-14 NHANES data, the overall serum triglyceride concentrations, but non-fasting prevalence of hypertriglyceridemia is 25.9%, and the serum triglycerides are perhaps more indicative prevalence in people treated with statins is 31.6%.12 of health risk. Many large epidemiologic studies The overall prevalence is still higher in men than in including the Women’s Health Initiative study and women
Load more

Recommended publications
  • Lipid Lowering Agents, Cognitive Decline, and Dementia: the Three-City Study
    Lipid lowering agents, cognitive decline, and dementia: the three-city study. Marie-Laure Ancelin, Isabelle Carrière, Pascale Barberger-Gateau, Sophie Auriacombe, Olivier Rouaud, Spiros Fourlanos, Claudine Berr, Anne-Marie Dupuy, Karen Ritchie To cite this version: Marie-Laure Ancelin, Isabelle Carrière, Pascale Barberger-Gateau, Sophie Auriacombe, Olivier Rouaud, et al.. Lipid lowering agents, cognitive decline, and dementia: the three-city study.: Lipid Lowering Agents and Cognitive Decline. Journal of Alzheimer’s Disease, IOS Press, 2012, 30 (3), pp.629-37. 10.3233/JAD-2012-120064. inserm-00707350 HAL Id: inserm-00707350 https://www.hal.inserm.fr/inserm-00707350 Submitted on 12 Jun 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Lipid lowering agents, cognitive decline, and dementia: the three-city study Marie-Laure Ancelin 1 * , Isabelle Carrière 1 , Pascale Barberger-Gateau 2 , Sophie Auriacombe 2 , Olivier Rouaud 3 , Spiros Fourlanos 4 , Claudine Berr 1 , Anne-Marie Dupuy 1 5 , Karen Ritchie 1 6 1 Neuropsychiatrie : Recherche Epidémiologique
    [Show full text]
  • Case Report: Eruptive Xanthoma in a 14-Year-Old Boy Ryan M
    Case Report: Eruptive Xanthoma in a 14-year-old boy Ryan M. Proctor, DO; Warren A. Peterson, DO; Michael W. Peterson, DO: Michael R. Proctor, DO; J. Ryan Jackson, DO; Andrew C. Duncanson OMS4; Allen E. Stout, DC. Dr. R. Proctor, Dr. W. Peterson, Dr. M. Peterson are from Aspen Dermatology Residency, Spanish Fork, UT; Dr. M. Proctor is from Arizona Desert Dermatology, Kingman, AZ; Dr. Jackson is from Sampson Regional Medical Center, Clinton, NC; OMS4 Duncanson is from Des Moines University, Des Moines, IA; DC Stout is from Stout Wellness Center, Fort Mohave, AZ. INTRODUCTION CLINICAL PHOTOS DISCUSSION Xanthomas are benign collections of lipid deposits that manifest as yellow to Eruptive xanthomas (EX) are often an indicator of severe red firm papules, nodules, or plaques. This yellow/red coloration is due to the hypertriglyceridemia and can indicate undiagnosed or Figure 1 Figure 2 carotene in lipids. Xanthomas are composed of lipid filled macrophages decompensated diabetes mellitus (DM).1 The triglyceride levels in known as “foam cells”. Xanthomas can be due to genetic disorders of lipid these patients can be >3000-4000 mg/dl (normal <150 mg/dl).2 metabolism, such as autosomal dominant hypocholesteremia or familial lipoprotein lipase(LPL) deficiency.1,2 They can also be caused by severe It is important to quickly diagnose and manage these patients due hypertriglyceridemia and have been associated with undiagnosed diabetic to the possible sequela of diabetes mellitus and hyperlipidemia. dyslipidemia, hypothyroidism, cholestasis, nephrotic
    [Show full text]
  • Genetic Testing for Familial Hypercholesterolemia AHS – M2137
    Corporate Medical Policy Genetic Testing for Familial Hypercholesterolemia AHS – M2137 File Name: genetic_testing_for_familial_hypercholesterolemia Origination: 01/01/2019 Last CAP Review: 07/2021 Next CAP Review: 07/2022 Last Review: 07/2021 Description of Procedure or Service Definitions Familial hypercholesterolemia (FH) is a genetic condition that results in premature atherosclerotic cardiovascular disease due to lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels (Sturm et al., 2018). FH encompasses multiple clinical phenotypes associated with distinct molecular etiologies. The most common is an autosomal dominant disorder caused by mutations in one of three genes, low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB), and proprotein convertase subtilisin-like kexin type 9 (PCSK9) (Ahmad et al., 2016; Goldberg et al., 2011). Rare autosomal recessive disease results from mutation in low-density lipoprotein receptor adaptor protein (LDLRAP) (Garcia et al., 2001). Related Policies Cardiovascular Disease Risk Assessment AHS – G2050 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial hypercholesterolemia when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Genetic Testing for Familial Hypercholesterolemia is covered 1. Genetic testing to establish a molecular diagnosis of Familial Hypercholesterolemia is considered medically necessary when BOTH of the following criteria are met: A.
    [Show full text]
  • Apoa5genetic Variants Are Markers for Classic Hyperlipoproteinemia
    CLINICAL RESEARCH CLINICAL RESEARCH www.nature.com/clinicalpractice/cardio APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia 1 1 1 2 2 1 1 Jian Wang , Matthew R Ban , Brooke A Kennedy , Sonia Anand , Salim Yusuf , Murray W Huff , Rebecca L Pollex and Robert A Hegele1* SUMMARY INTRODUCTION Hypertriglyceridemia is a common biochemical Background Several known candidate gene variants are useful markers for diagnosing hyperlipoproteinemia. In an attempt to identify phenotype that is observed in up to 5% of adults. other useful variants, we evaluated the association of two common A plasma triglyceride concentration above APOA5 single-nucleotide polymorphisms across the range of classic 1.7 mmol/l is a defining component of the meta­ 1 hyperlipoproteinemia phenotypes. bolic syndrome and is associated with several comorbidities, including increased risk of cardio­ Methods We assessed plasma lipoprotein profiles and APOA5 S19W and vascular disease2 and pancreatitis.3,4 Factors, –1131T>C genotypes in 678 adults from a single tertiary referral lipid such as an imbalance between caloric intake and clinic and in 373 normolipidemic controls matched for age and sex, all of expenditure, excessive alcohol intake, diabetes, European ancestry. and use of certain medications, are associated Results We observed significant stepwise relationships between APOA5 with hypertriglyceridemia; however, genetic minor allele carrier frequencies and plasma triglyceride quartiles. The factors are also important.5,6 odds ratios for hyperlipoproteinemia types 2B, 3, 4 and 5 in APOA5 S19W Complex traits, such as plasma triglyceride carriers were 3.11 (95% CI 1.63−5.95), 4.76 (2.25−10.1), 2.89 (1.17−7.18) levels, usually do not follow Mendelian patterns of and 6.16 (3.66−10.3), respectively.
    [Show full text]
  • Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor
    Page 1 of 50 Diabetes Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor Knockout Results in Progressive NAFLD Samir Softic1,2,#, Jeremie Boucher1,3,#, Marie H. Solheim1,4, Shiho Fujisaka1, Max-Felix Haering1, Erica P. Homan1, Jonathon Winnay1, Antonio R. Perez-Atayde5, and C. Ronald Kahn1. 1 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 2 Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA 3 Cardiovascular and Metabolic Diseases iMed, AstraZeneca R&D, 431 83 Mölndal, Sweden (current address) 4 KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway 5 Department of Pathology, Boston Children’s Hospital, and Harvard Medical School, Boston, MA # These authors contributed equally to this work. Corresponding author: C. Ronald Kahn, MD Joslin Diabetes Center One Joslin Place Boston, MA 02215 Phone: (617)732-2635 Fax:(617)732-2487 E-mail: [email protected] Keywords: Insulin receptors, IGF-1 receptors, lipodystrophy, diabetes, dyslipidemia, fatty liver, liver tumor, NAFLD, NASH. Running title: Lipodystrophic mice develop progressive NAFLD 1 Diabetes Publish Ahead of Print, published online May 10, 2016 Diabetes Page 2 of 50 SUMMARY Ectopic lipid accumulation in the liver is an almost universal feature of human and rodent models of generalized lipodystrophy and also is a common feature of type 2 diabetes, obesity and metabolic syndrome. Here we explore the progression of fatty liver disease using a mouse model of lipodystrophy created by a fat-specific knockout of the insulin receptor (F-IRKO) or both IR and insulin-like growth factor-1 receptor (F- IR/IGF1RKO).
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes
    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
    [Show full text]
  • The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: a Review
    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.26.004382 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: A Review Alaa Abousetta, Ibrahim Abousetta, Theresa Dobler, Lia Ebrahimi, Vassillis Frangoullis, Stephanos Christodoulides and Ioannis Patrikios* School of Medicine, European University Cyprus, Cyprus *Corresponding author: Ioannis Patrikios, School of Medicine, European University Cyprus, Cyprus ARTICLE INFO Abstract Received: March 06, 2020 Hypertriglyceridemia is a common problem in adults in the developed world. It is associated with increased levels of triglycerides within the blood, which subsequently Published: March 17, 2020 promote the development of other diseases such as cardiovascular disease and pancreatitis. Triglycerides are mostly consumed through the diet and act as a source of energy in between meals. However, the levels of triglycerides increase proportionally Citation: Alaa A, Ibrahim A, Theresa D, Lia with the number of calories consumed. This only leads to a problem if the total daily E, Ioannis P, et al., The Effect of Omega-3 energy expenditure is exceeded. Additionally, the type of macronutrients taken in Fatty Acids on Hypertriglyceridemia: A Re- view. Biomed J Sci & Tech Res 26(4)-2020. for instance, high carbohydrate intake has been associated with an increased plasma BJSTR. MS.ID.004382. triglyceridethrough the level.diet has If thea direct levels influence of the triglycerideson having an inincreased the blood level rise of abovetriglycerides, 150 mg/ as Abbreviations: FHTG: Familial hypertri- dL, it is considered as hypertriglyceridemia. Increasing numbers of triglycerides can glyceridemia; FCH: Familial Combined Hy- have multiple underlying causes, which can be divided into primary and secondary perlipidemia, systemic lupus erythemato- causes.
    [Show full text]
  • The Effects of Statin and Fibrate Drugs on Cholesterol Metabolism And
    The effects of statin and fibrate drugs on cholesterol metabolism and steroid production in two fish species. By Aziz Al-Habsi Thesis submitted to the Faculty of Graduate and Postdoctoral Studies University of Ottawa In partial fulfillment of the requirements for the PhD degree in the Ottawa-Carleton Institute of Biology Thèse soumise à la Faculté des Études Supérieurs et Postdoctorales Université d’Ottawa En vue de la réalisation partielle du doctorat à L’Institut de Biologie Ottawa-Carleton ©Aziz Al-Habsi, Ottawa, Canada, 2014 This thesis is dedicated to my wife and children who have always stood by me and dealt with all my absence from many family occasions with a smile. ii Acknowledgments Completing a PhD is truly a marathon event, and I would not have able to complete this journey without the aid and support of countless people over the past seven years. First and foremost I would like to gratefully and sincerely thank my supervisor Dr. Thomas W. Moon for his guidance, understanding, friendship, and most importantly, his patience during my graduate studies at University of Ottawa. His mentorship was paramount in providing a well-rounded experience consistent my long-term career goals. He encouraged me not only to be a biologist but also be an instructor and independent thinker. I am not sure many graduate students are given the opportunity to develop their own individuality and self- sufficiency by being allowed to work with such independence. For everything you’ve done for me, Dr. Moon, I thank you. I would like to extend my thanks the Department of Biology at University of Ottawa, especially those members of my doctoral committee for their input, valuable discussions and accessibility.
    [Show full text]
  • Pathophysiology of Adipocyte Defects and Dyslipidemia in HIV Lipodystrophy: New Evidence from Metabolic and Molecular Studies
    American Journal of Infectious Diseases 2 (3): 167-172, 2006 ISSN 1553-6203 © 2006 Science Publications Pathophysiology of Adipocyte Defects and Dyslipidemia in HIV Lipodystrophy: New Evidence from Metabolic and Molecular Studies 1,6Ashok Balasubramanyam, 1,6Rajagopal V. Sekhar, 2,3Farook Jahoor 4Henry J. Pownall and 5Dorothy Lewis 1Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, 2Department of Pediatrics, 3Children’s Nutrition Research Center 4Section of Atherosclerosis and Lipoprotein Metabolism, 5Department of Immunology Baylor College of Medicine; 6Endocrine Service, Ben Taub General Hospital, Houston, Texas Abstract: Despite a burgeoning mass of descriptive information regarding the epidemiology, clinical features, body composition changes, hormonal alterations and dyslipidemic patterns in patients with HIV lipodystrophy syndrome (HLS), the specific biochemical pathways that are dysregulated in the condition and the molecular mechanisms that lead to their dysfunction, remain relatively unexplored. In this paper, we review studies that detail the metabolic basis of the dyslipidemia - specifically, the hypertriglyceridemia - that is the serologic hallmark of HLS and present new data relevant to mechanisms of dyslipidemia in the postprandial state. We also describe preliminary experiments showing that in addition to the well-known effects of highly-active antiretroviral drugs, the functional disruption of adipocytes and preadipocytes by factors intrinsic to HIV-infected immunocytes may play a role in the pathogenesis of HLS. Key words: Triglycerides, cholesterol, lipoprotein lipase, lipolysis, lymphocyte INTRODUCTION Metabolic basis of HLS - studies in the fasting and fed state: Whole body kinetic studies have Characteristics of dyslipidemia and its relationship demonstrated defects in specific lipid metabolic [19-21] to lipodystrophy: A characteristic dyslipidemic pattern pathways in HLS patients in both the fasting and observed in the majority of patients with HLS is fed (25) states.
    [Show full text]
  • Lipoprotein Lipase: a General Review Moacir Couto De Andrade Júnior1,2*
    Review Article iMedPub Journals Insights in Enzyme Research 2018 www.imedpub.com Vol.2 No.1:3 ISSN 2573-4466 DOI: 10.21767/2573-4466.100013 Lipoprotein Lipase: A General Review Moacir Couto de Andrade Júnior1,2* 1Post-Graduation Department, Nilton Lins University, Manaus, Amazonas, Brazil 2Department of Food Technology, Instituto Nacional de Pesquisas da Amazônia (INPA), Manaus, Amazonas, Brazil *Corresponding author: MC Andrade Jr, Post-Graduation Department, Nilton Lins University, Manaus, Amazonas, Brazil, Tel: +55 (92) 3633-8028; E-mail: [email protected] Rec date: March 07, 2018; Acc date: April 10, 2018; Pub date: April 17, 2018 Copyright: © 2018 Andrade Jr MC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation: Andrade Jr MC (2018) Lipoprotein Lipase: A General Review. Insights Enzyme Res Vol.2 No.1:3 Abstract Lipoprotein Lipase: Historical Hallmarks, Enzymatic Activity, Characterization, and Carbohydrates (e.g., glucose) and lipids (e.g., free fatty acids or FFAs) are the most important sources of energy Present Relevance in Human for most organisms, including humans. Lipoprotein lipase (LPL) is an extracellular enzyme (EC 3.1.1.34) that is Pathophysiology and Therapeutics essential in lipoprotein metabolism. LPL is a glycoprotein that is synthesized and secreted in several tissues (e.g., Macheboeuf, in 1929, first described chemical procedures adipose tissue, skeletal muscle, cardiac muscle, and for the isolation of a plasma protein fraction that was very rich macrophages). At the luminal surface of the vascular in lipids but readily soluble in water, such as a lipoprotein [1].
    [Show full text]
  • Other Types of Primary Hyperlipoproteinemia
    82 Journal of Atherosclerosis and Thrombosis Vol.21, No.2 Committee Report 10 Other Types of Primary Hyperlipoproteinemia (Hyperlipidemia) Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ― 2012 Version Tamio Teramoto, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode and Koutaro Yokote Committee for Epidemiology and Clinical Management of Atherosclerosis 1. Primary Hyperlipoproteinemias (Hyperlipidemias) enhanced hepatic apolipoprotein (apo) B-100 synthe- Other Than Familial Hypercholesterolemia sis, decreased LPL activity, increased very-low-density There are various types of primary hyperlipopro- lipoprotein (VLDL) secretion from the liver and the teinemias (hyperlipidemias) other than familial hyper- accumulation of visceral fat as factors for the develop- cholesterolemia (FH). These types are clinically ment of symptoms and has been reported to be related important and classified according to their associated to abnormalities of the LPL and APOC-Ⅱ genes or pathophysiology and genetic abnormalities (Table 1)1). APOA-Ⅰ/C-Ⅲ/A-Ⅳ gene cluster. However, none of Familial lipoprotein lipase (LPL) deficiency manifests these findings have been proven to be definitive. It has as severe hyperchylomicronemia and may present with also been suggested that FCHL is caused by a poly- eruptive cutaneous xanthomas or acute pancreatitis, genic background that tends to induce hyperlipopro- although it does not necessarily accompany atheroscle- teinemia due to environmental factors, such as over- rotic cardiovascular disease (CVD). On the other nutrition and a low level of physical activity.
    [Show full text]